Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Capricor Therapeutics (CAPR) announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy, DMD, which were presented yesterday at the 2026 Muscular Dystrophy Association, MDA, Clinical & Scientific Conference in Orlando, Florida. MDA Presentation Highlights: Cardiac MRI analyses demonstrated Deramiocel’s impact on cardiac structure in patients with DMD. Evaluation of late gadolinium enhancement, a marker of myocardial fibrosis, showed a significant reduction in fibrotic segments in patients treated with Deramiocel versus placebo, corresponding to a three-segment treatment difference at 12 months. In patients with baseline cardiomyopathy, Deramiocel demonstrated an even greater treatment effect on cardiac function. A Global Statistical Test, a patient-level composite including Performance of Upper Limb, left ventricular ejection fraction, and Patient Global Impression of Severity, demonstrated a statistically significant overall treatment benefit favoring Deramiocel. Additional functional outcomes evaluating hand-to-mouth activity, an important measure of patient independence, were also presented.